Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-APOC-III-LRx in healthy volunteers with elevated triglycerides
NCT02900027Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertriglyceridemia comparing IONIS-APOC-III-LRx with Placebo (2 arms). Primary endpoint: Safety and tolerability of single and multiple doses of IONIS-APOC-III-LRx up to 183 days. Started Sep 2016; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT02900027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900027.